The revolutionary GLP-1 drugs are dramatically altering how Canadians eat and spend, a recent survey reveals! It seems these medications are no longer just a medical footnote; they're becoming a significant force in everyday life, impacting everything from our grocery lists to our dining-out habits.
Imagine this: a new poll suggests that a staggering three million Canadian adults are currently on GLP-1 medications like Ozempic or Mounjaro. And if you thought that was a lot, even more Canadians are eager to try them, but the high cost is proving to be a major hurdle for many.
This groundbreaking survey, conducted by Leger Healthcare, uncovered some fascinating insights. More than half of those taking these medications reported a noticeable decrease in their appetite. Even more striking, 40 per cent mentioned experiencing fewer food cravings. This isn't just about feeling less hungry; it's about a fundamental shift in how people relate to food.
And this is the part most people miss: these appetite-reducing effects are directly influencing spending patterns. Approximately 30 per cent of GLP-1 users are now dining out or ordering takeout less frequently. It’s a clear sign that when your relationship with food changes, so does your wallet!
Furthermore, the survey highlights a positive shift in dietary choices. About a third of users are actively purchasing more fresh fruits and vegetables, alongside an increase in protein-rich foods. It seems the desire for healthier options is on the rise, directly linked to the medication's influence.
Now, let's talk about the primary motivation. The No. 1 reason people are taking or considering GLP-1 medications is weight loss. Following closely behind is the management of diabetes. It's clear that these drugs are addressing significant health concerns for a large segment of the population.
But here's where it gets controversial: For those interested in starting GLP-1s, insurance coverage or the availability of lower-cost generic options would significantly sway their decision, according to over half of the respondents. This raises questions about accessibility and equity in healthcare. Should life-changing medications be out of reach for those who can't afford them?
Melicent Lavers-Sailly, vice-president of research at Leger Healthcare, aptly stated, “GLP-1s are no longer a niche health topic. They’re a mainstream consumer and health-care story.” She further emphasized, “What the research found is that the impact of GLP-1s is showing up in shopping baskets and behaviours, not just prescriptions.” This truly underscores the widespread impact these drugs are having.
Beyond dining habits, the survey reveals other behavioral changes. Around 35 per cent of individuals on these medications are ordering smaller portions, opting for “lighter or healthier options,” or simply not finishing their meals. Additionally, a notable 36 per cent have reported decreased alcohol consumption. It's a holistic shift affecting various aspects of lifestyle.
Interestingly, GLP-1 use is also influencing spending outside of the food sector. The survey indicates an increase in spending on clothes, personal care products, beauty services, and fitness. This suggests a broader sense of well-being and a desire to invest in oneself as a result of the medication's effects.
The survey also estimates that approximately two million Canadian adults are keen to try GLP-1s but are not currently taking them. This highlights a significant unmet demand.
While cost and lack of insurance are barriers for about half of those interested, another 36 per cent cited the risk of side-effects as a deterrent. Common gastrointestinal issues like nausea and constipation are reported, though doctors generally consider most side-effects to be minor. More severe complications, while rare, can include gall bladder inflammation and pancreatitis.
Revisiting the motivations, 58 per cent of people taking or considering GLP-1s are driven by weight loss, while 42 per cent are primarily focused on diabetes management. A smaller but significant group, 22 per cent, are taking them for heart health, with men being more likely to cite this benefit.
Financially, the burden is substantial. A quarter of respondents taking GLP-1s are paying the full cost, which can run into hundreds of dollars monthly, completely out of pocket. For 28 per cent, the medication is fully covered by insurance, while nearly half have partial coverage. This disparity in financial support is a critical point of discussion.
This online survey, conducted by Leger Healthcare between February 6th and 9th, 2026, involved 1,536 Canadians aged 18 and over. Eight per cent of respondents confirmed they were taking a prescription GLP-1 medication, which, when extrapolated using 2025 adult population data, translates to roughly three million Canadians. Similarly, six per cent expressed interest in taking GLP-1s but were not, suggesting over two million more Canadians could be potential users.
While online surveys don't have a traditional margin of error, Leger Healthcare notes that a comparable probability sample would typically yield a margin of error of ±2.5 per cent (19 times out of 20). This provides a general sense of the survey's reliability.
What are your thoughts on the widespread adoption of GLP-1 drugs? Do you believe they are a positive step forward for public health, or do you have concerns about their accessibility and long-term societal impact? Share your opinions below!
